Literature DB >> 32005658

Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease.

Xiaotian Zhong1, Srinath Jagarlapudi2, Yan Weng3, Mellisa Ly4, Jason C Rouse4, Kim McClure2, Tetsuya Ishino3, Yan Zhang3, Eric Sousa3, Justin Cohen3, Boriana Tzvetkova4, Kaffa Cote4, John J Scarcelli5, Keith Johnson4, Joe Palandra3, James R Apgar3, Suma Yaddanapudi2, Romer A Gonzalez-Villalobos2, Alan C Opsahl2, Khetemenee Lam3, Qing Yao3, Weili Duan3, Annette Sievers3, Jing Zhou3, Darren Ferguson3, Aaron D'Antona3, Richard Zollner3, Hongli L Zhu3, Ron Kriz3, Laura Lin3, Valerie Clerin6.   

Abstract

The fortuitously discovered antiaging membrane protein αKlotho (Klotho) is highly expressed in the kidney, and deletion of the Klotho gene in mice causes a phenotype strikingly similar to that of chronic kidney disease (CKD). Klotho functions as a co-receptor for fibroblast growth factor 23 (FGF23) signaling, whereas its shed extracellular domain, soluble Klotho (sKlotho), carrying glycosidase activity, is a humoral factor that regulates renal health. Low sKlotho in CKD is associated with disease progression, and sKlotho supplementation has emerged as a potential therapeutic strategy for managing CKD. Here, we explored the structure-function relationship and post-translational modifications of sKlotho variants to guide the future design of sKlotho-based therapeutics. Chinese hamster ovary (CHO)- and human embryonic kidney (HEK)-derived WT sKlotho proteins had varied activities in FGF23 co-receptor and β-glucuronidase assays in vitro and distinct properties in vivo Sialidase treatment of heavily sialylated CHO-sKlotho increased its co-receptor activity 3-fold, yet it remained less active than hyposialylated HEK-sKlotho. MS and glycopeptide-mapping analyses revealed that HEK-sKlotho is uniquely modified with an unusual N-glycan structure consisting of N,N'-di-N-acetyllactose diamine at multiple N-linked sites, one of which at Asn-126 was adjacent to a putative GalNAc transfer motif. Site-directed mutagenesis and structural modeling analyses directly implicated N-glycans in Klotho's protein folding and function. Moreover, the introduction of two catalytic glutamate residues conserved across glycosidases into sKlotho enhanced its glucuronidase activity but decreased its FGF23 co-receptor activity, suggesting that these two functions might be structurally divergent. These findings open up opportunities for rational engineering of pharmacologically enhanced sKlotho therapeutics for managing kidney disease.
© 2020 Zhong et al.

Entities:  

Keywords:  Klotho; LacdiNAc; acute kidney injury; fibroblast growth factor receptor (FGFR); glycosidase; glycosylation; mammalian cell expression; pharmacokinetics; sialic acid; signal transduction

Mesh:

Substances:

Year:  2020        PMID: 32005658      PMCID: PMC7062171          DOI: 10.1074/jbc.RA119.012144

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

Review 1.  The FGF23 and Klotho system beyond mineral metabolism.

Authors:  Makoto Kuro-O
Journal:  Clin Exp Nephrol       Date:  2016-11-12       Impact factor: 2.801

Review 2.  Renal and extrarenal actions of Klotho.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

3.  Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.

Authors:  Ke Yang; Cheng Wang; Ling Nie; Xiaohui Zhao; Jun Gu; Xu Guan; Song Wang; Tangli Xiao; Xinli Xu; Ting He; Xuefeng Xia; Junping Wang; Jinghong Zhao
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

4.  Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.

Authors:  Jian Xie; Joonho Yoon; Sung-Wan An; Makoto Kuro-o; Chou-Long Huang
Journal:  J Am Soc Nephrol       Date:  2014-12-04       Impact factor: 10.121

5.  Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.

Authors:  Ming Chang Hu; Mingjun Shi; Han Jun Cho; Beverley Adams-Huet; Jean Paek; Kathy Hill; John Shelton; Ansel P Amaral; Christian Faul; Masatomo Taniguchi; Myles Wolf; Markus Brand; Masaya Takahashi; Makoto Kuro-O; Joseph A Hill; Orson W Moe
Journal:  J Am Soc Nephrol       Date:  2014-10-17       Impact factor: 10.121

6.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

Review 7.  The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.

Authors:  Alexander Grabner; Christian Faul
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 8.  Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.

Authors:  Xiang Lu; Ming Chang Hu
Journal:  Kidney Dis (Basel)       Date:  2016-11-17

Review 9.  Update on FGF23 and Klotho signaling.

Authors:  Reinhold G Erben
Journal:  Mol Cell Endocrinol       Date:  2016-05-10       Impact factor: 4.102

10.  A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.

Authors:  Masashi Kitagawa; Hitoshi Sugiyama; Hiroshi Morinaga; Tatsuyuki Inoue; Keiichi Takiue; Ayu Ogawa; Toshio Yamanari; Yoko Kikumoto; Haruhito Adam Uchida; Shinji Kitamura; Yohei Maeshima; Kazufumi Nakamura; Hiroshi Ito; Hirofumi Makino
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

View more
  7 in total

1.  GWAS meta-analysis followed by Mendelian randomization revealed potential control mechanisms for circulating α-Klotho levels.

Authors:  Ingrid Gergei; Jie Zheng; Till F M Andlauer; Vincent Brandenburg; Nazanin Mirza-Schreiber; Bertram Müller-Myhsok; Bernhard K Krämer; Daniel Richard; Louise Falk; Sofia Movérare-Skrtic; Claes Ohlsson; George Davey Smith; Winfried März; Jakob Voelkl; Jonathan H Tobias
Journal:  Hum Mol Genet       Date:  2022-03-03       Impact factor: 6.150

2.  Abnormally decreased renal Klotho is linked to endoplasmic reticulum-associated degradation in mice.

Authors:  ShaSha Li; JiaWei Kong; LiXia Yu; QiFeng Liu
Journal:  Int J Med Sci       Date:  2022-01-09       Impact factor: 3.738

Review 3.  New Opportunities in Glycan Engineering for Therapeutic Proteins.

Authors:  Xiaotian Zhong; Aaron M D'Antona; John J Scarcelli; Jason C Rouse
Journal:  Antibodies (Basel)       Date:  2022-01-10

Review 4.  Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations.

Authors:  Gérald J Prud'homme; Mervé Kurt; Qinghua Wang
Journal:  Front Aging       Date:  2022-07-12

Review 5.  Mass spectrometry-based N-glycosylation analysis in kidney disease.

Authors:  Weifu Ren; Qi Bian; Yan Cai
Journal:  Front Mol Biosci       Date:  2022-08-17

Review 6.  The controversy of klotho as a potential biomarker in chronic kidney disease.

Authors:  Li-Xia Yu; Sha-Sha Li; Min-Yue Sha; Jia-Wei Kong; Jian-Ming Ye; Qi-Feng Liu
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

Review 7.  Klotho and calciprotein particles as therapeutic targets against accelerated ageing.

Authors:  Makoto Kuro-O
Journal:  Clin Sci (Lond)       Date:  2021-08-13       Impact factor: 6.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.